Annual report pursuant to Section 13 and 15(d)

Organization and Summary of Significant Accounting Policies - Additional Information (Detail)

v3.22.1
Organization and Summary of Significant Accounting Policies - Additional Information (Detail)
$ in Millions
12 Months Ended
Dec. 31, 2021
USD ($)
Segment
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Organization And Summary Of Significant Accounting Policies [Line Items]      
Loss on assets held for sale   $ 2.0  
Reportable segment | Segment 1    
Patents      
Organization And Summary Of Significant Accounting Policies [Line Items]      
Amortization expense $ 0.1 $ 0.1  
Estimated expense, next twelve months 0.1    
Estimated expense, year two 0.1    
Estimated expense, year three 0.1    
Estimated expense, year four $ 0.1    
In-process Research and Development      
Organization And Summary Of Significant Accounting Policies [Line Items]      
Impairment of long lived assets     $ 22.1
Leasehold Improvements | Minimum      
Organization And Summary Of Significant Accounting Policies [Line Items]      
Property and equipment, estimated useful lives 3 years    
Leasehold Improvements | Maximum      
Organization And Summary Of Significant Accounting Policies [Line Items]      
Property and equipment, estimated useful lives 7 years    
Revenue | Concentration of Credit Risk and Other Risks and Uncertainties | Takeda      
Organization And Summary Of Significant Accounting Policies [Line Items]      
Percentage of total revenues 34.00% 35.00%  
Revenue | Concentration of Credit Risk and Other Risks and Uncertainties | Vertex Pharmaceuticals Inc      
Organization And Summary Of Significant Accounting Policies [Line Items]      
Percentage of total revenues 48.00% 48.00%  
Revenue | Concentration of Credit Risk and Other Risks and Uncertainties | BMS      
Organization And Summary Of Significant Accounting Policies [Line Items]      
Percentage of total revenues 18.00% 0.00%  
Other Assets      
Organization And Summary Of Significant Accounting Policies [Line Items]      
Restricted cash $ 3.7 $ 3.7  
Gross value of patents $ 1.1 $ 1.2